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Glutamate antagonists limit the growth of human cancers in vitro.
The mechanism of anticancer action of NMDA antagonists is not known, however. In this article, we report that the NMDA antagonist dizocilpine inhibits the extracellular signal-regulated kinase 1͞2 pathway, an intracellular signaling cascade that is activated by growth factors and controls the proliferation of cancer cells. Dizocilpine reduces the phosphorylation of cAMP-responsive element binding protein, suppresses the expression of cyclin D1, up-regulates the cell cycle regulators and tumor suppressor proteins p21 and p53, and increases the number of lung adenocarcinoma cells in the G2 and S phases of the cell cycle. Silencing of the tumor suppressor protein p21 abolishes antiproliferative action of dizocilpine. Consistent with inhibition of the extracellular signalregulated kinase 1͞2-signaling cascade, dizocilpine reverses the stimulation of proliferation induced by epidermal, insulin, and basic fibroblast growth factors in lung adenocarcinoma cells. Furthermore, dizocilpine prolongs the survival of mice with metastatic lung adenocarcinoma and slows the growth of neuroblastoma and rhabdomyosarcoma in mice. These findings reveal the mechanism of antiproliferative action of dizocilpine and indicate that it may be useful in the therapy of human cancers.
cell cycle ͉ growth factors ͉ lung cancer ͉ signal transduction O ne of every three people in the world contracts cancer; of those individuals, one in four die. Advances in cancer management with chemotherapy, bone marrow transplantation, radiotherapy, and surgery have had only a modest effect on mortality, and therefore, the search for chemotherapeutics for cancer continues (1) . Anticancer drugs are cytotoxic and interfere with synthesis of DNA and cell division. Deregulated growth of cancers, however, may arise from mutations within the pathways that promote survival (2, 3) .
Glutamate regulates the proliferation, migration, and survival of neuronal progenitors and immature neurons during development (4, 5) . Glutamate activates ionotropic and metabotropic receptors. The ionotropic glutamate NMDA receptors assemble from subsets of two subunits, NR1 and NR2. The NR1 subunit imparts on heteromeric NMDA channels ion permeability, whereas the NR2 subunits A, B, C, and D determine electrophysiological properties of the channel (6) (7) (8) . NMDA receptors are expressed both in neurons and in nonneuronal tissues (6) . Activation of glutamate NMDA receptors in neurons is translated to the nucleus by the extracellular signal-regulated kinase (ERK1͞2)-signaling cascade leading to the phosphorylation of the cAMP-responsive element binding protein (CREB) and activation of genes promoting survival (9-12).
Glutamate NMDA antagonists block the channel function in a competitive or noncompetitive manner. Dizocilpine blocks NMDA receptor-associated channels in a noncompetitive manner regardless of the subunit composition of the channel (8) .
We determined that dizocilpine inhibits the ERK1͞2 pathway in cancer cells and reduces the phosphorylation of CREB and expression of CREB-regulated genes. These actions translate into the slowing of cell cycle progression and proliferation of cancer cells in vitro and achieve an anticancer effect in mice in vivo.
Materials and Methods
Cell Culture. Human Caucasian lung carcinoma A549 cells (Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland) were incubated with (ϩ)-dizocilpine (10-500 M; Sigma). Cells were exposed for 3 h to 10 M U0126 and 200 nM phorbol 12-myristate 13-acetate or for 6 h to 200 nM wortmannin, 50 M KN62 (Calbiochem), insulin growth factor (IGF; 100 ng͞ml; Sigma), epidermal growth factor (EGF; 10 ng͞ml; Sigma), basic fibroblast growth factor (bFGF; 10 ng͞ml; Sigma), or NMDA (10 M; Tocris Cookson, Bristol, U.K.). Human neuroblastoma (SKNAS) and human rhabdomyosarcoma͞medulloblas-toma (TE671) cells were obtained from the European Collection of Cell Cultures (ECACC; Center for Applied Microbiology and Research, Salisbury, U.K.). SKNAS and TE671 cells were grown in a 1:1 mixture of DMEM (D 6421, Sigma; 1.05 mM Ca 2ϩ concentration) and a nutrient mixture (Ham's F-12 medium, Sigma) supplemented with 10% FBS (GIBCO). For in vivo experiments, (ϩ)-dizocilpine was chosen because of its high efficacy and selectivity as a noncompetitive NMDA antagonist, its safety, and its pharmacokinetic properties (bioavailability and half-life time) allowing for two daily systemic administrations in rodents (13) . The plasma concentrations of (ϩ)-dizocilpine in in vivo experiments are lower than those applied in in vitro settings; however, the exposure of the tumor cells to (ϩ)-dizocilpine is longer in vivo.
Immunofluorescence and Cell Staining. A549 cells were grown on coverslips, incubated with 250 M dizocilpine for 3 h, fixed with 100% methanol (Ϫ20°C, 5 min), and probed with rabbit antiphospho-ERK1͞2 antibody (1:300 in 5% BSA͞Tris-buffered saline containing Tween 20; Cell Signaling Technology, Beverly, MA) or with rabbit anti-NR1 antibody (2.0 g͞ml in 1% BSA͞PBS; Chemicon International, Temecula, CA) and anti-NR2B antibody (1:250 in 1% BSA͞PBS; Santa Cruz Biotechnology), followed by incubation with chicken anti-rabbit Alexa Fluor 594 secondary antibody (5 g͞ml in 1% BSA͞TBS; Molecular Probes). Images were collected by using a two-photon confocal laser-scanning microscope (Leica, Vienna). Alexa Fluor 594 was excited by a mode-locked Ti͞ sapphire laser (Tsunami, Spectra-Physics) at wavelength 770 nm.
Flow Cytometry. A FACScan flow cytometer (Becton Dickinson) equipped with a 488-nm argon laser was used. Cells were stained with propidium iodide by using the CycleTEST PLUS DNA reagent kit (BD Pharmingen). Cell cycle analysis was performed by using noncommercial flow cytometry analyzing software (CYLCHRED 1.0.2 for Windows; Department of Hematology, Cardiff University, Wales, U.K.) and WINMDI 2.8 for Windows (Scripps Research Institute, La Jolla, CA). Cells were acquired and gated by using the dot plot fluorescence-2 width (x) vs. the fluorescence-2 area (y)-gate to exclude aggregates and analyzed in histograms displaying fluorescence-2 area (yellow-orange fluorescence, 585 nm).
Viability Assay. Cells were plated on 96-well microplates (Nunc) at a density of 1 ϫ 10 4 A549 cells per ml and exposed to IGF (100 ng͞ml; Sigma), EGF (10 ng͞ml; Sigma), or bFGF (10 ng͞ml; Sigma) alone or with 10 M dizocilpine (Sigma). Cells were also exposed to 50 ng of p21 small interfering RNA (siRNA) per well, diluted in GeneSilencer reagent, or exposed to GeneSilencer reagent (Gene Therapy Systems, San Diego) in growing medium with 10% FCS, according to the manufacturer's protocol. Cell proliferation was assessed after 48 -96 h by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide method (14) .
Proliferation Assay. Tumor cells were incubated with 10 mM BrdUrd (BrdUrd labeling and detection kit III, Roche Diagnostics) over 18 h, fixed with 0.5 M ethanol⅐HCl, and incubated with nucleases to digest DNA. Monoclonal anti-BrdUrd antibodies conjugated to peroxidase were added and detected by using a 2,2Ј-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) substrate. Quantitation was performed colorimetrically at 405-490 nm.
Cytotoxicity Assay. A cytotoxicity detection kit measuring the lactate dehydrogenase activity was used (Roche Diagnostics).
Western Blot Analysis. Cells were lysed in RIPA buffer (1% Nonidet P-40͞0.5% sodium deoxycholate͞0.1% SDS͞1 mM EDTA͞1 mM EGTA͞1 mM Na 3 VO 4 ͞20 mM NaF͞0.5 mM DTT͞1 mM PMSF͞ protease inhibitor mixture in PBS, pH 7.4) and centrifuged at 3,000 ϫ g for 10 min. Supernatants were solubilized in 3ϫ Laemmli sample buffer (30% glycerol͞3% SDS͞0.19 M Tris⅐HCl, pH 6.8͞ 0.015% bromophenol blue͞3% 2-mercaptoethanol) and boiled for 5 min at 100°C. Equal amounts of cellular protein extract were electrophoresed on 10% SDS͞PAGE under reducing conditions and transferred onto a nitrocellulose membrane (Schleicher and Schüll). After blocking for 1 h at room temperature with 5% nonfat dry milk͞TBS͞0.1% Tween 20, membranes were probed at 4°C with primary antibodies as follows: anti-phospho-ERK1͞2, antiphospho-mitogen-activated protein kinase (MEK), anti-phosphop90RSK, anti-phospho-CREB (Ser-133), anti-ERK1͞2, antiphospho-Akt (Ser-473), anti-Akt (1:1,000 in 1% BSA͞TBS͞0.1% Tween 20; Cell Signaling Technology), or anti-phospho-calmodulin kinase (CaMK)II (Thr-286), and anti-CaMKII and anti-ERK1͞2 (1:250 in 1% BSA͞1% nonfat dry milk͞TBS͞0.1% Tween 20; Santa Cruz Biotechnology), incubated with the secondary antibody coupled to horseradish peroxidase (1:5,000 in 1% BSA͞TBS͞0.1% Tween 20; Amersham Pharmacia Biosciences) and visualized by using enhanced chemiluminescence (ECL, Amersham Pharmacia Biosciences). Serial exposures were made on autoradiographic film (Hyperfilm ECL, Amersham Pharmacia Biosciences). Densitometric analysis of the blots was performed with the image analysis program TINA 2.09G (Raytest Isotopenmessgeräte, Straubenhardt, Germany). The sequence of oligonucleotide primers used in RT-PCR are shown in Table 1 .
Semiquantitative RT-PCR. RNA (500 ng) was reverse-transcribed with Moloney murine leukemia virus reverse transcriptase (Promega) and oligo d(T) 16 primer (Promega) in 25 l of reaction mixture. The resulting cDNA (1-2 l) was amplified by PCR for bcl-2, c-fos, c-jun, cyclin D1, p21, p53, NR1, NR2B, and ␤-actin. cDNA was amplified in 28-32 cycles, consisting of denaturing over 30 s at 94°C, annealing over 45 s at 52°C or 58°C, and primer extension over 45 s at 72°C. Amplified cDNA was subjected to polyacrylamide gel electrophoresis, silver staining, and densitometric analysis with the image analysis program BIODOC ANALYZE (Whatman Biometra, Göttingen, Germany).
siRNA Design and Transfection. p21 siRNA (5Ј-GACCAUGUG-GACCUGUCAC-3Ј) was designed by using the Eurogentec siRNA design service (Brussels) and in vitro-synthesized with the Silencer siRNA construction kit (Ambion, Austin, TX). Cells were plated at a density of 60% in 24-well plates the day before transfection. Transfection was carried out by using GeneSilencer (Gene Therapy Systems).
p21 Real-Time PCR. Real-time PCR of p21 was carried out by using TaqMan universal master mix (Applied Biosystems), as described by Sifringer et al. (15) . RNA samples were identical to those The GenBank accession nos. for the primers are as follows: bcl-2, BC027258; c-fos, V01512; c-jun, J04111; cyclin D1, NM053056; p21, AF497972; p53, X02469; NR1, L05666; NR2B, U88963; and ␤-actin, V01217.
described above. The used p21 TaqMan probe (5ЈFAM-CTTCGGCCCAGTGGACAG-TAMRA3Ј) and primers (forward primer: 5Ј-ACCCATGCGGCAGCAA-3Ј; reverse primer: 5Ј-CGCCATTAGCGCATCACA-3Ј) were designed and synthesized by Applied Biosystems. Amplification of an endogenous reference (18S rRNA TaqMan ribosomal RNA control reagents, Applied Biosystems) was performed. Reactions were carried out in triplicate in a 20-l volume and repeated twice by using the Applied Biosystems PRISM 7000 sequence detection system. The PCR amplification was performed in 96-well optical reaction plates for 40 cycles, each at 94°C for 20 s and 60°C for 1 min. Calibration curves for p21 and 18S rRNA were performed to determine the linear range of the assay. For relative comparison of the expression levels, the comparative C T method was used (Applied Biosystems, User Bulletin no. 2).
Tumor Growth in Rodents. In vivo studies in mice were approved by the Animal Use and Care Committee of Humboldt University. Animals were maintained under pathogen-free conditions. SCID͞ SCID mice (Charles River Breeding Laboratories, Sulzfeld, Germany), 4 weeks old, were inoculated with lung carcinoma (A549, 1 ϫ 10 7 cells) into the peritoneal cavity and administered either dizocilpine (0.03 or 0.1 mg͞kg, i.p.) or vehicle once a day. Nude mice (nu͞nu; Charles River Breeding Laboratories), 5 weeks old, were inoculated into the right flank with human neuroblastoma (SKNAS; 1 ϫ 10 7 cells per 0.1 ml of Hanks' balanced salt solution) or human rhabdomyosarcoma (TE671; 1 ϫ 10 7 cells per 0.1 ml of Hank's balanced salt solution) and randomized. Dizocipline was dissolved in saline and administered i.p. at 0.3 mg͞kg twice daily, beginning the day after tumor cell inoculation and continuing for 21 days. Tumor volume (V; cubed centimeters) was calculated by using the equation V ϭ d 2 ϫ D͞2, where d (squared centimeters) and D (centimeters) are the smallest and largest perpendicular diameters.
Statistics. One-and two-way ANOVA and Student's t test were used for comparisons. Survival data of tumor-bearing mice are presented as a Kaplan-Meier plot, and the log-rank test was applied for statistical analysis.
Results

Dizocilpine Inhibits Proliferation of Lung Carcinoma Cells in Vitro.
(ϩ)-Dizocilpine reduced viability of A549 cells in a concentrationdependent manner ( Fig. 1a ; exposure 96 h). (Ϫ)-Dizocilpine (Tocris Cookson), the less active stereoisomer of dizocilpine at NMDA receptors, was substantially less effective in preventing proliferation of tumor cells. Antiproliferative effect was elicited with memantine (Sigma), another NMDA receptor antagonist. Decreased BrdUrd incorporation in A549 cells and a mild increase in the lactate dehydrogenase activity in cultures exposed to (ϩ)-dizocilpine were evident (Fig. 1b) . Fluorescence confocal microscopy showed diffuse membrane and cytoplasmic staining for human NR1 and NR2B subunits (Fig. 1c) , which conforms with RT-PCR analysis demonstrating the expression of NR1 and NR2B mRNA (Fig. 1c) .
Dizocilpine Inhibits the ERK1͞2 Pathway. In A549 cells treated with 250 M (ϩ)-dizocilpine for 15 min to 24 h, decreased levels of phosphorylated ERK1͞2, MEK1͞2, and p90RSK became evident after 30 min and remained low for up to 24 h (Fig. 1d) . The level of total ERK1͞2 proteins was unaltered (Fig. 1d) . Confocal imaging confirmed a decrease of ERK1͞2 activity after dizocilpine treatment in A549 cells, resulting in more intense staining of unexposed cells compared with (ϩ)-dizocilpine-exposed cells (Fig. 1f ) . Quantification of the relative intensity of staining revealed that relative intensity decreased from 148.1 Ϯ 29.7 pixels per cell (n ϭ 18) in control cultures to 80.3 Ϯ 20.6 pixels per cell (n ϭ 15) in cultures exposed to (ϩ)-dizocilpine (P Ͻ 0.001; Student's t test). Translocation of phosphorylated ERK1͞2 into the nucleus was abolished in cells incubated with 250 M (ϩ)-dizocilpine over 3 h (Fig. 1f ) .
To investigate whether the observed ERK1͞2 inhibition was concentration-dependent, A549 cells were incubated with different concentrations of (ϩ)-dizocilpine (10-500 M) for 3 h. A concentration-dependent decrease of ERK1͞2 phosphorylation was observed between 100 and 500 M (Fig. 1e) .
Decreased CREB Phosphorylation After Treatment with Dizocilpine.
CREB controls transcription of immediate early genes (9, 16) and plays a role in tumor progression (17, 18) . Phosphorylation on Ser-133 by p90RSK kinase is critical for positive regulation of the transcriptional activity of CREB. Decrease of the p90RSK activity was followed by the hypophosphorylation of CREB in A549 cells (Fig. 1d) . To evaluate the possible involvement of CaM kinases in CREB hypophosphorylation (19) , CaMKII phosphorylation was analyzed by immunoblotting. No significant changes in the activities of CaMKII were detected when A549 cells were incubated with 250 M (ϩ)-dizocilpine for 15 min every 24 h (Fig. 2a) . KN62 (50 M), which directly binds to the calmodulin binding site of the enzyme, inhibited the activity of CaMKII (Fig. 2a) . Inhibition of CaMKII and CaMKIV with KN62 had no impact on CREB phosphorylation (Fig. 2a) . No changes in the phosphorylation of Akt kinase, which has also been shown to phosphorylate CREB (20) , were detected. Akt phosphorylation was inhibited when cells were incubated with 200 nM wortmannin for 6 h (Fig. 2a) . Wortmannin did not inhibit CREB phosphorylation, whereas (ϩ)-dizocilpine inhibited CREB phosphorylation markedly (Fig. 2a) . These results indicate that inhibition of ERK1͞2 kinases by (ϩ)-dizocilpine results in inhibition of CREB phosphorylation at Ser-133.
Dizocilpine Decreases the Expression of CREB-Regulated Genes.
CREB has been implicated in the transcriptional control of genes involved in cell proliferation, such as c-fos and cyclin D1 (21) . Activation of NMDA receptors in neuronal cells results in CREBdependent expression of the prosurvival gene bcl-2 (11) . We studied the expression of bcl-2, c-fos, and c-jun mRNA by using RT-PCR analysis in A549 cells exposed to (ϩ)-dizocilpine. After a 24-h exposure to 250 M (ϩ)-dizocilpine, all three gene products decreased in A549 cells (c-fos reduced to 50% and c-jun and bcl-2 to 40% of basal levels; Fig. 2 b and c) . Members of Fos and Jun families form the AP1 transcription factor, which regulates cell proliferation and cell cycle progression through induction of cyclin D1 transcription and repression of p53 gene expression followed by 
repression of p21
Cip1 transcription (22, 23) . Therefore, it is possible that (ϩ)-dizocilpine, by down-regulating c-fos͞c-jun (AP1) expression, also affects the expression of AP1-regulated genes. Changes in the expression of cyclin D1, p53, and p21 after 24 h of exposure to (ϩ)-dizocilpine were found (Fig. 2 c and d) . Cyclin D1 expression was reduced to 60% of the basal level, and p53 and p21 gene transcription was increased 2-and 3-fold, respectively. Consequently, (ϩ)-dizocilpine affected the cell cycle (Fig. 2e) . The percentage of cells in the G 2 and S phase decreased significantly from 53.2 Ϯ 0.3% to 44.9 Ϯ 0.8% or 39.0 Ϯ 1.5% after 250 M or 500 M (ϩ)-dizocilpine, respectively (P Ͻ 0.001; Student's t test). Concomitantly, the percentage of resting cells (G 1 ) increased from 46.8 Ϯ 0.3% to 55.1 Ϯ 0.8% (250 M dizocilpine) or 61.0 Ϯ 1.5% (500 M dizocilpine) (P Ͻ 0.001; Student's t test).
Silencing of p21 Ameliorates Antiproliferative Action of Dizocilpine.
To confirm the functional significance of p21 up-regulation, we investigated whether p21-silencing would reverse the antiproliferative action of (ϩ)-dizocilpine. siRNA oligos were designed complementary to human p21 mRNA. At 48 h after transfection of A549 cells, reduction of the p21 protein was confirmed by Western blot analysis (Fig. 3a) . Real-time PCR analysis revealed decreased levels of p21 mRNA (Fig. 3a) . A significant increase (P Ͻ 0.001; Student's t test) in the cell viability after silencing of p21 was detected compared with nontransfected A549 cells exposed to transfection reagent only (gene-silencing reagent) (data not shown). Exposure to 250 M (ϩ)-dizocilpine over 48 h resulted in an additional significant reduction of the cell viability. (ϩ)-Dizocilpine slightly reduced the cell viability of p21 siRNAtransfected A549 cells (P Ͻ 0.05), but the level of inhibition was lower compared with nontransfected cells (Fig. 3b) .
Dizocilpine reverses the stimulatory effect of the growth factors. The ERK1͞2 pathway mediates the cell proliferation and survival in response to the growth factors. We investigated how A549 cells respond to the growth factors and whether (ϩ)-dizocilpine influences their effect. IGF (100 ng͞ml), EGF (10 ng͞ml), or bFGF (10 ng͞ml) stimulated tumor cell proliferation, which is revealed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay (96-h exposure). In the presence of (ϩ)-dizocilpine (10 M), no such growth stimulatory effect was seen (Fig. 3c) . Of note is that these concentrations of the NMDA antagonist did not influence proliferation or levels of phosphorylated ERK and CREB when given in the absence of the growth factors (Fig. 3c) . Increased phosphorylation of ERK1͞2 and CREB was found in A549 cells 
